Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Revenue	$ 765,900	$ 212,418
Operating expenses:
Cost of revenues	611,740
Research and development	6,995,848	3,933,347
Selling, general and administrative	6,820,550	3,776,623
Amortization of intangible asset	363,750
Change in fair value of contingent consideration	(990,500)	(21,000)
Total operating expenses	13,801,388	7,688,970
Loss from operations	(13,035,488)	(7,476,552)
Change in fair value of warrant liability		7,779
Interest income	51,030	115,568
Unrealized loss on available-for-sale securities	89,322	(836,593)
Total non-operating income (loss)	140,352	(713,246)
Net loss before income taxes	(12,895,136)	(8,189,798)
Net loss	(12,895,136)	(8,189,798)
Net loss - non-controlling interest	(110,489)	(69,211)
Net loss attributable to NightHawk Biosciences, Inc.	$ (12,784,647)	$ (8,120,587)
Net loss per share, basic (in dollars per share)	$ (0.49)	$ (0.32)
Net loss per share, diluted (in dollars per share)	$ (0.49)	$ (0.32)
Weighted-average common shares outstanding, basic (in shares)	25,971,143	25,593,948
Weighted-average common shares outstanding, diluted (in shares)	25,971,143	25,593,948
Comprehensive loss:
Net loss	$ (12,895,136)	$ (8,189,798)
Unrealized gain (loss) on foreign currency translation	31,963	(55,269)
Total comprehensive loss	(12,863,173)	(8,245,067)
Comprehensive loss attributable to non-controlling interest	(110,489)	(69,211)
Comprehensive loss - NightHawk Biosciences, Inc.	$ (12,752,684)	$ (8,175,856)